Exhibit 107
Calculation of Filing Fee Tables
Form F-3
…………..
(Form Type)
Altamira Therapeutics Ltd.
……………………………………………………..…
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Amount to be Registered (1) | Proposed Maximum Offering Price Per Unit (2) | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | Carry Forward Form Type | Carry Forward File Number | Carry Forward Initial effective date | Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward | |
Newly Registered Securities | ||||||||||||
Fees to Be Paid | Equity | Common shares, par value CHF 0.01 per share (3) | 457(c) | 2,777,986 | $1.06 | $2,944,665 | 0.0000927 | $273 | -– | – | – | – |
Fees Previously Paid | – | – | – | – | – | – | – | – | – | – | – | – |
Carry Forward Securities | ||||||||||||
Carry Forward Securities | – | – | – | – | – | – | – | – | – | – | – | – |
Total Offering Amounts | $2,944,665 | $273 | ||||||||||
Total Fees Previously Paid | – | |||||||||||
Total Fee Offsets | – | |||||||||||
Net Fee Due | $273 |
(1) | Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers an indeterminable number of additional securities that may become issuable pursuant to terms designed to prevent dilution resulting from share splits, share dividends or similar events. | |
(2) | Estimated in accordance with Rule 457(c) under the Securities Act solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the registrant’s common shares, as reported on the Nasdaq Capital Market on April 8, 2022, a date within five business days prior to the initial filing of this registration statement on April 14, 2022. | |
(3) | Consists of 2,777,986 common shares that may be acquired upon one or more conversions under the Convertible Loan Agreement, dated February 4, 2022, by and between the Altamira Therapeutics Ltd. and FiveT Investment Management Ltd. |